FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896548727> ?p ?o ?g. }

• W2896548727 endingPage "183" @default.
• W2896548727 startingPage "171" @default.
• W2896548727 abstract "Integration of multimodal therapies into one nanoplatform holds great promise to overcome the drawbacks of conventional single-modal therapy and pursues enhanced anticancer efficacy. Herein, we developed a PEGylated gold nanorods (GNRs)-based nanoplatform (GNRs-MPH-ALA/DOX-PEG) with pH-responsive drug release property for triple-combined chemotherapy (CT), photodynamic therapy (PDT) and photothermal therapy (PTT) of breast cancer. GNRs were first decorated with mercaptopropionylhydrazide (MPH) and thiol-terminated monomethoxyl poly(ethylene glycol) (mPEG-SH) via Au-thiol linkage, and subsequently conjugated with chemotherapeutant doxorubicin (DOX) and pro-photosensitizer 5-aminolevulinic acid (ALA) through acid-liable hydrazone bonds between drugs and MPH molecules. The resulting nanoplatform GNRs-MPH-ALA/DOX-PEG exhibited excellent stability in physiological solutions and pH-responsive DOX and ALA release behaviors. In vitro studies showed that GNRs-MPH-ALA/DOX-PEG could efficiently enter human breast cancer MCF-7 cells and release DOX and ALA into cytoplasm. Furthermore, DOX could locate in the cell nucleus and ALA was productively metabolized into protoporphyrin IX (PpIX). Upon near-infrared (NIR) irradiation, PpIX produced enough reactive oxygen species for PDT and meanwhile GNRs could efficiently induce hyperthermia for PTT. Compared with single CT and dual-modal CT/PDT or CT/PTT treatment, the triple-combined CT/PDT/PTT treatment could more efficiently kill MCF-7 cells via a superadditive antitumor effect. Furthermore, the circulation half-life of GNRs-MPH-ALA/DOX-PEG in the blood was as long as approximately 52 min and it exhibited a tumor accumulation of 3.3%. The triple-combined CT/PDT/PTT treatment could completely suppress tumor growth without obvious systemic toxicity. Our study paves a new avenue for multimodal therapy of breast cancer. STATEMENT OF SIGNIFICANCE: The development of a simple but effective strategy to construct a versatile nanoplatform for multi-combined therapy still remains an enormous challenge. In this work, we developed a novel and simple nanoplatform GNRs-MPH-ALA/DOX-PEG with pH-responsive drug release for triple-combined chemotherapy (CT), photodynamic therapy (PDT) and photothermal therapy (PTT) of breast cancer. The nanoplatform could be efficiently internalized by MCF-7 cells. The intracellular GNRs-MPH-ALA/DOX-PEG could release DOX for CT, induce hyperthermia for PTT and generate high levels of ROS for PTT. Compared with single CT and dual-modal CT/PDT or CT/PTT treatments, the triple-combined CT/PDT/PTT treatment could more efficiently kill MCF-7 cells via a superadditive antitumor effect. Furthermore, upon triple-combined CT/PDT/PTT treatment, the tumor growth was completely suppressed without obvious systemic toxicity." @default.
• W2896548727 created "2018-10-26" @default.
• W2896548727 creator A5005120665 @default.
• W2896548727 creator A5020504109 @default.
• W2896548727 creator A5030221994 @default.
• W2896548727 creator A5038824956 @default.
• W2896548727 creator A5047123907 @default.
• W2896548727 creator A5072667148 @default.
• W2896548727 creator A5074589952 @default.
• W2896548727 creator A5082456616 @default.
• W2896548727 creator A5086161254 @default.
• W2896548727 date "2018-12-01" @default.
• W2896548727 modified "2023-10-16" @default.
• W2896548727 title "PEGylated hydrazided gold nanorods for pH-triggered chemo/photodynamic/photothermal triple therapy of breast cancer" @default.
• W2896548727 cites W1933261099 @default.
• W2896548727 cites W1964250581 @default.
• W2896548727 cites W1964836370 @default.
• W2896548727 cites W1967604695 @default.
• W2896548727 cites W1980052502 @default.
• W2896548727 cites W1981932250 @default.
• W2896548727 cites W1986504105 @default.
• W2896548727 cites W1994023367 @default.
• W2896548727 cites W2016081404 @default.
• W2896548727 cites W2033156964 @default.
• W2896548727 cites W2041459061 @default.
• W2896548727 cites W2043166795 @default.
• W2896548727 cites W2054432852 @default.
• W2896548727 cites W2060238699 @default.
• W2896548727 cites W2060286198 @default.
• W2896548727 cites W2073916105 @default.
• W2896548727 cites W2076895064 @default.
• W2896548727 cites W2077768338 @default.
• W2896548727 cites W2081788400 @default.
• W2896548727 cites W2093359612 @default.
• W2896548727 cites W2094676926 @default.
• W2896548727 cites W2126036312 @default.
• W2896548727 cites W2156641530 @default.
• W2896548727 cites W2158231500 @default.
• W2896548727 cites W2176513311 @default.
• W2896548727 cites W2254154401 @default.
• W2896548727 cites W2273459564 @default.
• W2896548727 cites W2299387502 @default.
• W2896548727 cites W2314906766 @default.
• W2896548727 cites W2328886593 @default.
• W2896548727 cites W2329353330 @default.
• W2896548727 cites W2341002190 @default.
• W2896548727 cites W2406824978 @default.
• W2896548727 cites W243711793 @default.
• W2896548727 cites W2549628327 @default.
• W2896548727 cites W2554294021 @default.
• W2896548727 cites W2557857134 @default.
• W2896548727 cites W2561143729 @default.
• W2896548727 cites W2571556434 @default.
• W2896548727 cites W2572422139 @default.
• W2896548727 cites W2586185458 @default.
• W2896548727 cites W2586289265 @default.
• W2896548727 cites W2587161721 @default.
• W2896548727 cites W2592761639 @default.
• W2896548727 cites W2605872386 @default.
• W2896548727 cites W2606734676 @default.
• W2896548727 cites W2613352698 @default.
• W2896548727 cites W2614666068 @default.
• W2896548727 cites W263751706 @default.
• W2896548727 cites W2748629068 @default.
• W2896548727 cites W2754000801 @default.
• W2896548727 cites W2763046181 @default.
• W2896548727 cites W2768662807 @default.
• W2896548727 cites W2769705286 @default.
• W2896548727 cites W2776575854 @default.
• W2896548727 cites W2784243986 @default.
• W2896548727 cites W2790341795 @default.
• W2896548727 cites W2793067479 @default.
• W2896548727 cites W2793815895 @default.
• W2896548727 cites W2794373765 @default.
• W2896548727 cites W2801862810 @default.
• W2896548727 cites W2884616676 @default.
• W2896548727 cites W923668049 @default.
• W2896548727 doi "https://doi.org/10.1016/j.actbio.2018.10.019" @default.
• W2896548727 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30336271" @default.
• W2896548727 hasPublicationYear "2018" @default.
• W2896548727 type Work @default.
• W2896548727 sameAs 2896548727 @default.
• W2896548727 citedByCount "50" @default.
• W2896548727 countsByYear W28965487272019 @default.
• W2896548727 countsByYear W28965487272020 @default.
• W2896548727 countsByYear W28965487272021 @default.
• W2896548727 countsByYear W28965487272022 @default.
• W2896548727 countsByYear W28965487272023 @default.
• W2896548727 crossrefType "journal-article" @default.
• W2896548727 hasAuthorship W2896548727A5005120665 @default.
• W2896548727 hasAuthorship W2896548727A5020504109 @default.
• W2896548727 hasAuthorship W2896548727A5030221994 @default.
• W2896548727 hasAuthorship W2896548727A5038824956 @default.
• W2896548727 hasAuthorship W2896548727A5047123907 @default.
• W2896548727 hasAuthorship W2896548727A5072667148 @default.
• W2896548727 hasAuthorship W2896548727A5074589952 @default.
• W2896548727 hasAuthorship W2896548727A5082456616 @default.
• W2896548727 hasAuthorship W2896548727A5086161254 @default.

• next